Episode Details
Back to EpisodesGT Biopharma ($GTBP) CEO on FDA Approval for New Investigational Drug Trial for Solid Tumor Cancer
Description
This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.
Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company’s expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.
Explore GT Biopharma: https://www.gtbiopharma.com/
Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5g
And follow us to stay updated: https://www.youtube.com/GlobalOneMedia